Research areas
► government ethics and the regulation of health care (e.g., conflicts of interest, lobbying, revolving door, transparency)
► Food and Drug Administration (FDA)
► technologies (e.g., drugs, devices, AI, cybersecurity)
Metholodogical approach
► guided by economic and sociological theory
► quantitative (statistical / econometric) methods
► large administrative, survey, and other datasets
Recent Activity
>> New Publication <<
March 7, 2025
Unregulated large language models produce medical device-like output. npj Digital Medicine 2025; 4:148.
>> New Publication <<
September 20, 2024
Lessons from the Change Healthcare Ransomware Attack. JAMA Health Forum 2024; 5:e242764.
Public Comment
August 13, 2024
Comment on Optimizing the FDA’s Use of and Processes for Advisory Committees [Docket No. FDA-2024-N-1809]
PricePod: Public Policy Conversations (podcast)
June 4, 2025
Closing the revolving door at HHS
Interview with Christian Hetrick
Cincinnati Enquirer
May 18, 2025
Nearly 60% of doctors take money from Big Pharma. Is your doctor one? [PDF]
by Elizabeth B. Kim
BioSpace
April 21, 2025
Banning industry from FDA adcomms won’t ‘move the needle much’ in Makary, RFK’s fight against COIs
by Heather McKenzie